Rangan Gopala, Allman-Farinelli Margaret, Boudville Neil, Fernando Mangalee, Haloob Imad, Harris David C H, Hawley Carmel M, Kumar Karthik, Johnson David W, Lee Vincent W, Mai Jun, Rangan Anna, Roger Simon D, Sagar Priyanka, Sud Kamal, Torres Vicente, Vilayur Eswari
Centre for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia.
Department of Renal Medicine, Westmead Hospital, Western Sydney Local Health District, Sydney, Australia.
Clin Kidney J. 2024 Jun 7;17(7):sfae159. doi: 10.1093/ckj/sfae159. eCollection 2024 Jul.
The aim of this study was to determine the long-term effect of increasing water intake in patients with autosomal dominant polycystic kidney disease (ADPKD) on longitudinal changes in health-related quality of life (HRQoL) in the setting of a clinical trial.
Self-completed HRQoL (using the KDQoL-SF, v.1.3 questionnaire) was assessed annually in participants of a 3-year randomized controlled clinical trial ( = 187), allocated (1:1) either to increase water intake to reduce urine osmolality to ≤270 mosmol/kg (implemented by dietetic coaching, self-monitoring tools, text messaging) or continue usual water intake.
Overall, 96% and 81.8% of participants ( = 187) completed the questionnaire at the baseline and final study visits, respectively. At baseline, the physical component summary score (PCS) and mental component summary score (MCS) were similar in the two groups (> 0.05) and the five dimensions with the lowest scores in both groups were: energy and fatigue; general and overall health; sleep; emotional well-being; and pain. Within each group, there were no longitudinal changes over time. At the final visit, the PCS was higher in the increased water intake group (51.3 ± 7.6, mean ± standard deviation) compared to the usual water intake group 48.8 ± 9.3; = 0.037) whereas the MCS was numerically similar. The improvement in the PCS was due to higher sub-scale values for physical functioning and pain (both < 0.05). By multivariate analysis, only baseline PCS and height-corrected total kidney volume were associated with the final PCS (< 0.05).
HRQoL scores remained stable over a 3 year period, and were not adversely affected by the intervention to increase water intake. Future studies should evaluate the clinical significance of the higher PCS in the increased water intake group.
本研究的目的是在一项临床试验的背景下,确定增加常染色体显性多囊肾病(ADPKD)患者的饮水量对健康相关生活质量(HRQoL)纵向变化的长期影响。
在一项为期3年的随机对照临床试验(n = 187)的参与者中,每年评估一次自我完成的HRQoL(使用KDQoL-SF,第1.3版问卷),参与者被(1:1)分配到增加饮水量以将尿渗透压降低至≤270 mosmol/kg组(通过饮食指导、自我监测工具、短信实施)或继续常规饮水量组。
总体而言,分别有96%和81.8%的参与者(n = 187)在基线和最终研究访视时完成了问卷。在基线时,两组的身体成分总结得分(PCS)和心理成分总结得分(MCS)相似(P>0.05),两组得分最低的五个维度是:精力与疲劳;总体健康状况;睡眠;情绪健康;和疼痛。在每组中,随时间没有纵向变化。在最终访视时,增加饮水量组的PCS高于常规饮水量组(51.3±7.6,平均值±标准差),而常规饮水量组为48.8±9.3;P = 0.037),而MCS在数值上相似。PCS的改善归因于身体功能和疼痛的子量表值较高(均P<0.05)。通过多变量分析,只有基线PCS和身高校正后的总肾体积与最终PCS相关(P<0.05)。
HRQoL评分在3年期间保持稳定,且未受到增加饮水量干预的不利影响。未来的研究应评估增加饮水量组中较高PCS的临床意义。